Phase Genomics
Facts
- HQ
- Washington, USA
- Sectors
- Biotechnology, Genomics, Life Sciences
- Founded
- 2015 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Phase Genomics Inc Seattle business license
- Stage
- startup
- Total raised
- $5.8M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $4.8M · Mar 2023 SEC Form D
- Founders
- Ivan Liachko, Jay Shendure, PhD, Maitreya Dunham, PhD
Washington Research Foundation Commits $1.7M to Renew UW–WSU Postdoctoral Entrepreneurship Collaboration
The Washington Research Foundation has committed $1.7 million over three years to support the UW CoMotion–WSU Postdoctoral Entrepreneurship Program, building on a prior $1.2 million grant in 2023. This funding supports postdoctoral researchers with mentorship and training to foster innovation, entrepreneurship, and commercialization across Washington's research institutions.
Phase Genomics Secures $2.5M to Develop AI Platform for Detecting Cancer Chromosomal Aberrations
Seattle startup Phase Genomics received $2.5 million in funding, including $2 million from the U.S. National Cancer Institute and $500,000 from Washington state's Andy Hill CARE Fund, to advance its AI-driven platform that detects chromosomal aberrations in cancer. The funding supports projects analyzing tumor samples to develop predictive scores for cancers like acute myeloid leukemia and colorectal cancer.
Grin Lord, CEO of Seattle’s mpathic, Finalist for Startup CEO of the Year at 2023 GeekWire Awards for Empathy-Driven Communication Software
Grin Lord, CEO and co-founder of Seattle startup mpathic, specializes in using empathy to improve corporate communication and is a finalist for Startup CEO of the Year at the 2023 GeekWire Awards. Her company applies machine learning to analyze conversations and foster empathy across industries such as insurance, healthcare, and human resources.
GeekWire Awards Reveal 2023 Startup CEO of the Year Finalists from Rebellyous Foods, Humanly, and Others
The 2023 GeekWire Awards announced finalists for Startup CEO of the Year, including leaders from startups in plant-based foods, mental health, employee communication, DNA analysis, and candidate screening automation. Voting continues until May 1, with winners revealed at the May 18 awards event hosted by Astound Business Solutions.
Seattle Startup Leaders Rate Economic Impact from -1 to 8 Amidst Shaky Market at Allen Institute AI Event
Seattle tech startups reported varying impacts from economic uncertainty at an Allen Institute AI-hosted event, with some scaling back while others find growth opportunities. Startup leaders rated the economic impact between -1 and 8, reflecting differing industry challenges and company stages.
Phase Genomics wins $3.9M in NIH grants to advance Hi-C and AI tests for chromosomal abnormalities
Seattle biotech Phase Genomics received $3.9 million in NIH grants to fund three-year projects using Hi-C proximity ligation and AI to detect chromosomal abnormalities linked to infertility and cancers.
Madrona hires ex-AWS product manager Anu Sharma as principal; Saykara and DomainTools add senior marketing and leadership hires
Madrona Venture Group hired Anu Sharma as a principal from AWS; Seattle startups and tech companies also announced hires and promotions, including Saykara naming Joy Efron VP of marketing and DomainTools adding four executives (CTO James Reynolds, CCO Jeff Day, VP of product Jackie Abrams, and VP of people Jill Boon).
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
Phase Genomics CEO Ivan Liachko shifts company to R&D focus after pandemic hits revenue; one furlough, no layoffs
Phase Genomics, a five-year-old University of Washington spinoff led by CEO Ivan Liachko, shifted to skeleton lab crews and remote work during the pandemic, cutting revenue and furloughing one employee while focusing R&D inward to adapt and continue innovating. The company is adjusting its genomics technology amid Seattle's biotech disruption and exploring ways to help with COVID-19 research.
People
-
Ivan Liachko Executive, CEO, Executive Officer, Director, Promoter
